Literature DB >> 23777589

A comparison of surgical outcomes for noncirrhotic and cirrhotic hepatocellular carcinoma patients in a Western institution.

Rachel E Beard1, Douglas W Hanto, Shiva Gautam, Rebecca A Miksad.   

Abstract

BACKGROUND: Although cirrhosis is common among Western hepatocellular carcinoma (HCC) patients, a substantial proportion are not cirrhotic. Studies examining surgical outcomes in noncirrhotic patients primarily evaluate Asian populations and liver resections. We describe cirrhotic and noncirrhotic HCC patients undergoing resection and transplantation at a Western institution.
METHODS: We retrospectively reviewed 188 HCC patients treated surgically from 2000 to 2011 at a single Western institution. The primary endpoint was recurrence. Secondary endpoints included time to recurrence and overall survival.
RESULTS: We evaluated 138 cirrhotic and 50 noncirrhotic patients with a median follow-up of 33.8 months. Noncirrhotics mostly underwent liver resection (90%), whereas cirrhotics primarily underwent transplantation (67%). Hepatitis B was the most common underlying liver disease for noncirrhotics (64%), whereas hepatitis C (55%) and alcohol abuse (32%) predominated among cirrhotics. Pathologic evaluation demonstrated tumors in noncirrhotics that were fewer in number, larger, less differentiated, and more likely to have vascular invasion. Recurrence was more common for noncirrhotics (36 vs. 18%; P = .008) and more common after resection compared with transplantation. Overall median survival was 46.9 months for both groups. After resection, noncirrhotics had longer survival times than did cirrhotics (41.6 vs. 32.9 months; P = .04). Vascular invasion was an independent predictor for recurrence; tumor size was a predictor of mortality.
CONCLUSION: Noncirrhotics in our Western cohort had higher risk pathologic features, more frequently underwent resection, and suffered more recurrences than did cirrhotics. Overall survival was similar for both groups. Prospective studies of noncirrhotic HCC patients in Asia and Western countries may inform surveillance and treatment.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23777589     DOI: 10.1016/j.surg.2013.02.019

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  12 in total

Review 1.  Hepatocellular carcinoma review: current treatment, and evidence-based medicine.

Authors:  Ali Raza; Gagan K Sood
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Distinguished prognosis after hepatectomy of HBV-related hepatocellular carcinoma with or without cirrhosis: a long-term follow-up analysis.

Authors:  Sheng-Li Yang; Li-Ping Liu; Yun-Fan Sun; Xing-Rong Yang; Jia Fan; Jian-Wei Ren; George G Chen; Paul B S Lai
Journal:  J Gastroenterol       Date:  2015-11-25       Impact factor: 7.527

3.  Mortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry.

Authors:  Hans-Christian Pommergaard; Andreas Arendtsen Rostved; René Adam; Allan Rasmussen; Mauro Salizzoni; Miguel Angel Gómez Bravo; Daniel Cherqui; Paolo De Simone; Pauline Houssel-Debry; Vincenzo Mazzaferro; Olivier Soubrane; Juan Carlos García-Valdecasas; Joan Fabregat Prous; Antonio D Pinna; John O'Grady; Vincent Karam; Christophe Duvoux; Lau Caspar Thygesen
Journal:  Liver Cancer       Date:  2020-05-12       Impact factor: 11.740

4.  Transcatheter arterial chemoembolization combined with CT-guided percutaneous thermal ablation versus hepatectomy in the treatment of hepatocellular carcinoma.

Authors:  Sheng Li; Liang Zhang; Zhi-Mei Huang; Pei-Hong Wu
Journal:  Chin J Cancer       Date:  2015-06-10

5.  Impact of age on the prognosis after liver transplantation for patients with hepatocellular carcinoma: a single-center experience.

Authors:  Pusen Wang; Chunguang Wang; Hao Li; Baojie Shi; Jianning Wang; Lin Zhong
Journal:  Onco Targets Ther       Date:  2015-12-16       Impact factor: 4.147

6.  Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma.

Authors:  Ivan Fan-Ngai Hung; Danny Ka-Ho Wong; Ronnie Tung-Ping Poon; Daniel Yee-Tak Fong; Ada Hang-Wai Chui; Wai-Kay Seto; James Yan-Yue Fung; Albert Chi-Yan Chan; John Chi-Hang Yuen; Randal Tiu; Olivia Choi; Ching-Lung Lai; Man-Fung Yuen
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

Review 7.  Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.

Authors:  Po-Chih Yang; Cheng-Maw Ho; Rey-Heng Hu; Ming-Chih Ho; Yao-Ming Wu; Po-Huang Lee
Journal:  World J Hepatol       Date:  2016-11-08

8.  Comparison of survival outcomes of alcohol-related hepatocellular carcinoma with or without liver cirrhosis; a ten-year experience.

Authors:  Jongbeom Shin; Jung Hwan Yu; Young-Joo Jin; Myoung Hun Chae; Chang Hwi Yoon; Jin-Woo Lee
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

9.  AROS Is a Significant Biomarker for Tumor Aggressiveness in Non-cirrhotic Hepatocellular Carcinoma.

Authors:  Jung-Hee Kwon; Keun Soo Ahn; Young Ho Moon; Jin Young Park; Hee Jung Wang; Kwan Yong Choi; Gundo Kim; Jae Won Joh; Kyeong Geun Lee; Koo Jeong Kang
Journal:  J Korean Med Sci       Date:  2015-08-13       Impact factor: 2.153

10.  Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative-intent surgery for hepatocellular carcinoma: experience from a developing country.

Authors:  Danijel Galun; Aleksandar Bogdanovic; Jelena Djokic Kovac; Predrag Bulajic; Zlatibor Loncar; Marinko Zuvela
Journal:  Cancer Manag Res       Date:  2018-05-04       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.